Campath CAM203

A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia

(1) A diagnosis of B-CLL; according to the NCIWG Criteria (Appendix D, protocol).
(2) At least 18 years old.
(3) World Health Organization (WHO) performance status of 0, 1, or 2.
(4) Life expectancy =12 weeks.
(5) Previous therapy with at least one but no more than 5 regimens (single agent or combination
regimen). One regimen is defined as consecutive, contiguous cycles of the same drug(s) with no
treatment interruptions lasting >3 months.
(6) Patient requires treatment for chronic lymphocytic leukemia (CLL) per the following criteria:
- Rai stage III or IV (Appendix D, protocol).
- Rai stage 0-II with at least one of the following:
• Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
• Massive (i.e., >6 cm below the left costal margin) or progressive splenomegaly
• Progressive lymphocytosis with an increase of >50% over a 2-month period or an anticipated doubling time of <6 months
• Lymphocyte count >100 × 109/L
• B symptoms
(7) More than 3 weeks since prior chemotherapy. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
(8) More than 3 weeks since using investigational agents. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
(9) Serum creatinine and conjugated (direct) bilirubin =2 × the institutional upper limit of normal (ULN) unless secondary to direct infiltration of the liver with CLL.
(10) Female patients with childbearing potential must have a negative pregnancy test (serum or urine) within 2 weeks of first dose of study drug(s). All patients must agree to use an effective
contraceptive method while on study treatment, if appropriate, and for a minimum of 6 months following study therapy.
(11) Signed, written informed consent.

(1) Positive Coombs test and evidence of active hemolysis.
(2) Platelet count <50 × 109/L without splenomegaly.
(3) History of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanized monoclonal antibodies.
(4) Previously treated with CAMPATH.
(5) Previous bone marrow transplant.
(6) Known central nervous system (CNS) involvement with B-CLL.
(7) Active infection, including human immunodeficiency virus (HIV) positive.
(8) Active second malignancy.
(9) Recent documented history (within 2 years) of active tuberculosis (TB), current active TB infection, currently receiving anti-tuberculosis medication (e.g., isoniazid, rifampin, streptomycin,
pyrazinamide, or others).
(10) Active hepatitis or a history of prior viral hepatitis B or hepatitis C, or positive hepatitis B serologies. Patients with a positive hepatitis B surface antibody (HBsAb) test with a documented
history of prior hepatitis B immunization are eligible as long as other criteria are met (i.e., negative tests for: hepatitis B surface antigen [HBsAg], hepatitis B core antibody [HBcAb] and hepatitis C
virus antibody [HCVAb]).
(11) Other severe, concurrent diseases (e.g., cardiac or pulmonary disease), mental disorders, or major organ malfunction (e.g., liver, kidney) that could interfere with the patient’s ability to participate in
the study.
(12) Pregnant or nursing women.
(13) Cytomegalovirus (CMV) positive by polymerase chain reaction (PCR) (above the level of detection). A patient that is PCR positive will require treatment to reduce the viral load to a
non-detectable level, but such a patient may be reconsidered for study entry once the infection has
been treated (see Section 6.1.1, protocol).
(14) Medical condition requiring chronic use of oral corticosteroids at a dose higher than physiologic replacement.

Principal Investigator

Dr Peter Hillmen

Tel 0113 2068513

Email peter.hillmen@leedsth.nhs.uk

Research Nurse

Alex Stichler

Tel 0113 2068577

Email alex.stichler@leedsth.nhs.uk

Print this page

Email this page to a colleague